Literature DB >> 18185830

Escitalopram in obsessive-compulsive disorder: a case series.

Amit Zutshi1, Suresh Bada Math, Y C Janardhan Reddy.   

Abstract

Entities:  

Year:  2007        PMID： 18185830      PMCID： PMC2139927          DOI： 10.4088/pcc.v09n0611c

Source DB:  PubMed          Journal:  Prim Care Companion J Clin Psychiatry        ISSN： 1523-5998


× No keyword cloud information.
  16 in total

Review 1.  Current treatments of the anxiety disorders in adults.

Authors:  J C Ballenger
Journal:  Biol Psychiatry       Date:  1999-12-01       Impact factor: 13.382

2.  Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessive-compulsive disorder.

Authors:  S A Montgomery; S Kasper; D J Stein; K Bang Hedegaard; O M Lemming
Journal:  Int Clin Psychopharmacol       Date:  2001-03       Impact factor: 1.659

3.  Escitalopram 10 mg/day is effective and well tolerated in a placebo-controlled study in depression in primary care.

Authors:  A Wade; O Michael Lemming; K Bang Hedegaard
Journal:  Int Clin Psychopharmacol       Date:  2002-05       Impact factor: 1.659

Review 4.  Mechanisms of action of current and potential pharmacotherapies of obsessive-compulsive disorder.

Authors:  Mostafa El Mansari; Pierre Blier
Journal:  Prog Neuropsychopharmacol Biol Psychiatry       Date:  2006-01-20       Impact factor: 5.067

Review 5.  Escitalopram: a review of its use in the management of anxiety disorders.

Authors:  Sohita Dhillon; Lesley J Scott; Greg L Plosker
Journal:  CNS Drugs       Date:  2006       Impact factor: 5.749

6.  Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder.

Authors:  Daniel A Geller; Joseph Biederman; S Evelyn Stewart; Benjamin Mullin; Andrés Martin; Thomas Spencer; Stephen V Faraone
Journal:  Am J Psychiatry       Date:  2003-11       Impact factor: 18.112

Review 7.  The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10.

Authors:  D V Sheehan; Y Lecrubier; K H Sheehan; P Amorim; J Janavs; E Weiller; T Hergueta; R Baker; G C Dunbar
Journal:  J Clin Psychiatry       Date:  1998       Impact factor: 4.384

Review 8.  Treatment non-response in OCD: methodological issues and operational definitions.

Authors:  Stefano Pallanti; Eric Hollander; Carol Bienstock; Lorrin Koran; James Leckman; Donatella Marazziti; Michele Pato; Dan Stein; Joseph Zohar
Journal:  Int J Neuropsychopharmacol       Date:  2002-06       Impact factor: 5.176

Review 9.  A review of pharmacologic treatments for obsessive-compulsive disorder.

Authors:  Alicia Kaplan; Eric Hollander
Journal:  Psychiatr Serv       Date:  2003-08       Impact factor: 3.084

10.  Escitalopram: a second-generation SSRI.

Authors:  Michael J Owens; Jerrold F Rosenbaum
Journal:  CNS Spectr       Date:  2002-04       Impact factor: 3.790
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.